Abstract
Objective
To assess the cost-effectiveness of ranibizumab compared with pegaptanib in the treatment of patients with minimally classic/occult neovascular age-related macular degeneration (AMD), from a societal perspective in Spain.
Methods
We constructed a Markov model with five states defined by visual acuity (VA) in the better-seeing eye (Snellen scale): VA >20/40, ≤20/40 to >20/80, ≤20/80 to >20/200, ≤20/200 to >20/400, ≤20/400, and an additional death state. Two cohorts of patients were distributed along the VA states, and treated with either ranibizumab or pegaptanib. Transition probabilities assigned for movement between these states with both drugs were obtained from published randomized clinical trials. Medical costs related to AMD treatment and follow-up, medical costs related to AMD comorbidities, and non-medical-related costs were taken into account. Costs (2008 Euro), health outcomes (Quality-adjusted life years—QALYs), both discounted at a 3.5% annual rate, and incremental cost-effectiveness ratios (ICER: €/QALY), were determined for a lifetime horizon in the base case analysis. Sensitivity analyses were conducted to explore different scenarios and assumptions in the model.
Results
Treating patients with varying degrees of visual impairment with monthly ranibizumab instead of pegaptanib was €71,206 more costly and provided 2.437 additional QALYs (€29,224/QALY). When administered on an as-needed basis, as in the Prospective Optical Coherence Tomography Imaging of Patients with Neovascular AMD Treated with Intraocular Ranibizumab (PrONTO) trial, the cost per QALY gained with ranibizumab was reduced to €4,623.
Conclusions
The cost per QALY gained with monthly ranibizumab compared with pegaptanib in the minimally classic/occult neovascular AMD population is just below the €30,000 threshold below which new drugs are sometimes regarded as cost-effective strategies in Spain. In this model, the key variables with greater impact on the cost-effectiveness results were the selected time horizon and the chosen extrapolation method, the source for data on pegaptanib efficacy and the number of ranibizumab injections. When administered on an as-needed basis, ranibizumab was a cost-effective strategy compared to pegaptanib in this population.
Similar content being viewed by others
References
Resnikoff S, Pascolini D, Etya’ale D, Kocur I, Pararajasegaram R, Pokharel G, Mariotti S (2004) Global data on visual impairment in the year 2002. Bull World Health Organ 82:844–849
Jager RD, Mieler WF, Miller JW (2008) Age-related macular degeneration. N Engl J Med 358:2606–2617
Ip MS, Scott IU, Brown GC, Brown MM, Ho AC, Huang SS, Recchia FM (2008) Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology 115:1837–1846
Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351:2805–2816
Chakravarthy U, Adamis AP, Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Patel M (2006) Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 113(1508):e1501–e1525
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431
Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444
Bashshur ZF, Bazarbachi A, Schakal A, Haddad ZA, El Haibi CP, Noureddin BN (2006) Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 142:1–9
Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ (2006) Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26:383–390
Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113(363–372):e365
Schouten JS, La Heij EC, Webers CA, Lundqvist IJ, Hendrikse F (2009) A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 247:1–11
Lynch SS, Cheng CM (2007) Bevacizumab for neovascular ocular diseases. Ann Pharmacother 41:614–625
Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN (2008) Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 145:249–256
Comparison of AMD Treatments Trials (CATT): Lucentis - Avastin Trial. National Eye Institute. Available at: http://www.nei.nih.gov/CATT. Accesed: 23rd of June, 2009
Brown GC, Brown MM, Brown HC, Kindermann S, Sharma S (2007) A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration. Ophthalmology 114:1170–1178
Hernandez-Pastor L, Ortega A, Garcia-Layana A, Giraldez J (2008) Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration. Clin Ther 30:2436–2451
Briggs A, Sculpher M (1998) An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 13:397–409
Sculpher MJ, Claxton K, Drummond M, McCabe C (2006) Whither trial-based economic evaluation for health care decision making? Health Econ 15:677–687
Arias L, Armada F, Donate J, Garcia-Arumi J, Giralt J, Pazos B, Pinero A, Martinez F, Mondejar JJ, Ortega I, Zlateva G, Buggage R (2008) Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss. Eye 23:326–333
Tablas de supervivencia de la población española. Instituto Nacional de Estadística [National Statistics Institute]. Available at: http://www.ine.es/jaxi/tabla.do?path=/t20/p319a/1992-2005/l0/&file=01001.px&type=pcaxis. Accesed: 4th of June 2009
Drummond M, Sculpher M, Torrance G, O’Brien B, Stoddart G (2005) Economic evaluation using decision analytic modelling. In: Methods for the economic evaluation of health care programmes, 3rd ed. Oxford University Press, Oxford, pp 277–314
Cruess AF, Zlateva G, Xu X, Soubrane G, Pauleikhoff D, Lotery A, Mones J, Buggage R, Schaefer C, Knight T, Goss TF (2008) Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study. Pharmacoeconomics 26:57–73
Pesos españoles y coste SNS. Año 2005. Ministerio de Sanidad y Consumo. [Health Ministry]. Available at: http://www.msc.es. Accesed: 26th december 2008
Indice de precios de consumo. Instituto Nacional de Estadística [National Statistics Institute]. Available at: http://www.ine.es/daco/ipc.htm. Accesed: 4th june 2009
Drummond M, Sculpher M, Torrance G, O’Brien B, Stoddart G (2005) Basic types of economic evaluation. In: Methods for the economic evaluation of health care programmes, 3rd ed. Oxford University Press, Oxford, pp 7–26
Brown GC, Sharma S, Brown MM, Kistler J (2000) Utility values and age-related macular degeneration. Arch Ophthalmol 118:47–51
NICE. Guide to the methods of technology appraisal, june 2008. Available at: http://www.nice.org.uk. Accesed: 26th december 2008
Briggs AH (2000) Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17:479–500
Mills E, Heels-Ansdell D, Kelly S, Guyatt G (2007) A randomized trial of Pegaptanib sodium for age-related macular degeneration used an innovative design to explore disease-modifying effects. J Clin Epidemiol 60:456–460
Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M (2007) An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 143:566–583
Rosenfeld PJ (2007) Ranibizumab: The Pronto study. American Academy of Ophthalmology. New Orleans, 10–13th November 2007
Quiram PA, Hassan TS, Williams GA (2007) Treatment of naive lesions in neovascular age-related macular degeneration with pegaptanib. Retina 27:851–856
Birch S, Gafni A (2006) Information created to evade reality (ICER): things we should not look to for answers. Pharmacoeconomics 24:1121–1131
McCabe C, Claxton K, Culyer AJ (2008) The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics 26:733–744
Soto Alvarez J (2004) New drugs in Spain – when are they to be considered cost-effective alternatives and profitable investments for the National Health System? Farm Hosp 28:299–304 [In Spanish]
Brown DM, Regillo CD (2007) Anti-VEGF Agents in the Treatment of Neovascular Age-related Macular Degeneration: Applying Clinical Trial Results to the Treatment of Everyday Patients. Am J Ophthalmol 144:627–637
Bhisitkul RB (2006) Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol 90:1542–1547
Drummond M, Sculpher M (2005) Common methodological flaws in economic evaluations. Med Care 43:5–14
Raftery J, Clegg A, Jones J, Tan SC, Lotery A (2007) Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness. Br J Ophthalmol 91:1244–1246
Acknowledgement
We are grateful to Donna Leverone, PharmD., for her writing assistance.
Financial support
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
MEETING PRESENTATION: An abstract of this article was presented at the Spanish Ophthalmology Society Annual Meeting, which took place in Sevilla, Spain, on 24–27 September, 2008.
Rights and permissions
About this article
Cite this article
Hernández-Pastor, L.J., Ortega, A., García-Layana, A. et al. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 248, 467–476 (2010). https://doi.org/10.1007/s00417-009-1156-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-009-1156-9